About Us
Our Values & Culture
Our Values & Culture
Our Values & Culture
EpiDestiny is founded on the principle that good science can and should translate into highly effective yet non-toxic treatments, accessible even to patients in low-income countries. We seek strategic partnerships needed for efficient clinical execution and worldwide commercialization.
Company Overview
Our Values & Culture
Our Values & Culture
We are a clinical-stage biopharmaceutical company. Our non-cytotoxic epigenetic drugs leverage the master transcription factor content of diseased cells to restore functional, healthy states, per the Hippocratic dictum “Natural forces within us are the true healers of disease”.
We have already generated clinical proof-of-principle that
We are a clinical-stage biopharmaceutical company. Our non-cytotoxic epigenetic drugs leverage the master transcription factor content of diseased cells to restore functional, healthy states, per the Hippocratic dictum “Natural forces within us are the true healers of disease”.
We have already generated clinical proof-of-principle that our science can and does translate into non-toxic, highly effective clinical treatment for severe non-malignant as well as malignant diseases.
EpiDestiny was founded in 2015 by Yogen Saunthararajah. As a physician-founded company, our driving principle is using science to meet severe unmet clinical needs, in a way that is kind and cost-effective, and without killing cells (cytotoxicity), since preservation of normal dividing cells is essential to health and a normal life-span.
EPI01
Our Values & Culture
EPI01
Our first drug: EPI01
is an orally available,
non-toxic, timed-release combination small molecule product.
EPI01 to treat Sickle Cell Disease and β-thalassemia is being developed in partnership with Novo Nordisk (Research Collaboration Agreement).
EpiDestiny is developing EPI01 and other noncytotoxic epigenetic therapeutics to treat c
Our first drug: EPI01
is an orally available,
non-toxic, timed-release combination small molecule product.
EPI01 to treat Sickle Cell Disease and β-thalassemia is being developed in partnership with Novo Nordisk (Research Collaboration Agreement).
EpiDestiny is developing EPI01 and other noncytotoxic epigenetic therapeutics to treat chemo- and radiation-resistant liquid and solid tumor malignancies.
Clinical Studies and Activities
